Clinical Trial Update: SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study) [Phase 4]

View source ↗

Summary

Phase 4 diabetic sub-study evaluating the XIENCE V everolimus-eluting coronary stent system in de novo coronary lesions; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Disease, Coronary Artery Disease | Phase 4 | Status: COMPLETED | Results posted: 2010-10-21